Disruptive animal health provider delivering innovative diagnostic solutions to veterinarians and pet owners across the United States.
Clinical-stage biotechnology company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV).
Clinical-stage biotechnology company focused on enabling cures with hematopoietic stem cell therapies.
Merged with Amplitude Healthcare Acquisition Corporation in 2021
Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.
Completed IPO in 2021
Clinical-stage biotechnology company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways.
Clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer.
Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.
Completed IPO in 2021
Commercial-stage specialty pharmaceutical company focused on pain management and adjacent specialty therapeutics areas.
Acquired by Zydus in 2017
Commercial-stage specialty ophthalmic company focused on innovative and impactful branded prescription products targeting the anterior segment of the eye.
Acquired by Santen in 2020
Commercial-stage specialty pharmaceutical company focused on gastrointestinal, dermatological, and women’s health products.
Commercial-stage specialty pharmaceutical company focused on the central nervous system (CNS), orphan diseases, and conditions with high unmet medical need.